Dr. Bex is a urologic surgeon at the Specialist Centre For Kidney Cancer, Royal Free London BEX,NHS Foundation Trust and a Professor at University College London, Division of Surgery and Interventional Science, London, UK and is affiliated with the Netherlands Cancer Institute, Amsterdam, The Netherlands. After receiving his MD degree at the University of Aachen, Germany in 1990 he followed his training at the Department of Urology, University of Essen Medical School and West German Comprehensive Cancer Centre. He was licensed as urologic surgeon in 1996. Subsequently, he specialized further in genitourinary oncology. His clinical research interest focuses on advanced renal cell carcinoma and the combination of targeted therapy and surgery. Dr. Bex has been the PI of the EORTC trial 30073 SURTIME which has reported at ESMO in Madrid in 2017. He is the PI of a neoadjuvant study with immunecheckpoint inhibitor combination therapy and steering committee member of several international phase 3 adjuvant trials in high risk renal cell carcinoma.
In collaboration with the Department of Immunology and the department of Angiogenesis Research at the Free University Amsterdam Dr. Bex is investigating primary tumour tissues after pretreatment with regard to the effect of the TKI’s on the immune system and angiogenesis. This has led to a collaboration with the Department of Genitourinary Oncology at the MD Anderson and the Bartholomew’s Hospital in London who are carrying out similar trials.
Dr. Bex is Vice-Chair of the European Association of Urology (EAU) Renal Cancer Guideline panel, Chair of the Genitourinary Group of the European Organization for Research and Treatment of Cancer (EORTC) and member of Dutch and German national urological associations. He is a reviewer for European Urology, British Journal of Urology, Urology, Lancet and Lancet Oncology.